CytoMed discloses non-dilutive investment for LongevityBank

CytoMed Therapeutics Limited furnished a Form 6-K noting it issued a press release on November 6, 2025.

Accepted by SEC EDGAR 11/06/2025 - 08:00 AM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

CytoMed Therapeutics Limited furnished a Form 6-K noting it issued a press release on November 6, 2025. The update announces a non-dilutive investment for its subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd and provides updates on its new China strategy.

The press release is included as Exhibit 99.1 titled “CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy.”

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GDTC announce in its Form 6-K?

It reported a press release announcing a non-dilutive investment for subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd and updates on its new China strategy.

Which CytoMed subsidiary is involved in the update?

LongevityBank Pte Ltd.

Who is providing the non-dilutive investment mentioned by GDTC?

ICH Capital Pte Ltd.

When was the press release issued by CytoMed Therapeutics?

November 6, 2025.

What exhibit contains the press release in the Form 6-K?

Exhibit 99.1.

What is the focus of CytoMed’s strategic update?

Updates on its new China strategy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On November 6, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing that it secures non-dilutive investment for its subsidiary LongevityBank Pte Ltd from ICH Capital Pte Ltd, as well as updates on its new China strategy.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description

99.1		Press Release dated November 6, 2025, titled: “CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy”

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited

	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: November 6, 2025	Title:	Director and Chairman

Source: View Original Filing on SEC EDGAR